176 related articles for article (PubMed ID: 30085081)
1. Ebola Virus Shed Glycoprotein Triggers Differentiation, Infection, and Death of Monocytes Through Toll-Like Receptor 4 Activation.
Iampietro M; Santos RI; Lubaki NM; Bukreyev A
J Infect Dis; 2018 Nov; 218(suppl_5):S327-S334. PubMed ID: 30085081
[TBL] [Abstract][Full Text] [Related]
2. Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection.
Iampietro M; Younan P; Nishida A; Dutta M; Lubaki NM; Santos RI; Koup RA; Katze MG; Bukreyev A
PLoS Pathog; 2017 May; 13(5):e1006397. PubMed ID: 28542576
[TBL] [Abstract][Full Text] [Related]
3. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
4. Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice.
Li W; Ye L; Carrion R; Mohan GS; Nunneley J; Staples H; Ticer A; Patterson JL; Compans RW; Yang C
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S398-403. PubMed ID: 25877553
[TBL] [Abstract][Full Text] [Related]
5. Ebola images emerge from the cave.
Diamond MS; Fremont DH
Cell Host Microbe; 2008 Aug; 4(2):87-9. PubMed ID: 18692765
[TBL] [Abstract][Full Text] [Related]
6. [Research progress on ebola virus glycoprotein].
Ding GY; Wang ZY; Gao L; Jiang BF
Bing Du Xue Bao; 2013 Mar; 29(2):233-7. PubMed ID: 23757858
[TBL] [Abstract][Full Text] [Related]
7. Correlates of vaccine-induced protective immunity against Ebola virus disease.
Medaglini D; Santoro F; Siegrist CA
Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831
[TBL] [Abstract][Full Text] [Related]
8. Shed GP of Ebola virus triggers immune activation and increased vascular permeability.
Escudero-Pérez B; Volchkova VA; Dolnik O; Lawrence P; Volchkov VE
PLoS Pathog; 2014 Nov; 10(11):e1004509. PubMed ID: 25412102
[TBL] [Abstract][Full Text] [Related]
9. The secret life of viral entry glycoproteins: moonlighting in immune evasion.
Cook JD; Lee JE
PLoS Pathog; 2013; 9(5):e1003258. PubMed ID: 23696729
[No Abstract] [Full Text] [Related]
10. Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans.
Vu H; Shulenin S; Grolla A; Audet J; He S; Kobinger G; Unfer RC; Warfield KL; Aman MJ; Holtsberg FW
Antiviral Res; 2016 Feb; 126():55-61. PubMed ID: 26681387
[TBL] [Abstract][Full Text] [Related]
11. Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages.
Olejnik J; Forero A; Deflubé LR; Hume AJ; Manhart WA; Nishida A; Marzi A; Katze MG; Ebihara H; Rasmussen AL; Mühlberger E
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331091
[TBL] [Abstract][Full Text] [Related]
12. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
[TBL] [Abstract][Full Text] [Related]
13. Positive evolution of the glycoprotein (GP) gene is related to transmission of the Ebola virus.
Jing YX; Wang LN; Wu XM; Song CX
Genet Mol Res; 2016 Mar; 15(1):. PubMed ID: 27051001
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a Candidate Ebola Hemorrhagic Fever Vaccine in Mice Based on Controlled In Vitro Expression of Ebolavirus Glycoprotein.
Kumar D; Gauthami S; Uma M; Nagalekshmi K; Rao PP; Basu A; Ella KM; Hegde NR
Viral Immunol; 2018 Sep; 31(7):500-512. PubMed ID: 30095362
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
[TBL] [Abstract][Full Text] [Related]
16. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis.
Feldmann H; Volchkov VE; Volchkova VA; Klenk HD
Arch Virol Suppl; 1999; 15():159-69. PubMed ID: 10470276
[TBL] [Abstract][Full Text] [Related]
17. A GXXXA Motif in the Transmembrane Domain of the Ebola Virus Glycoprotein Is Required for Tetherin Antagonism.
González-Hernández M; Hoffmann M; Brinkmann C; Nehls J; Winkler M; Schindler M; Pöhlmann S
J Virol; 2018 Jul; 92(13):. PubMed ID: 29669839
[TBL] [Abstract][Full Text] [Related]
18. The roles of ebolavirus glycoproteins in viral pathogenesis.
Ning YJ; Deng F; Hu Z; Wang H
Virol Sin; 2017 Feb; 32(1):3-15. PubMed ID: 27853993
[TBL] [Abstract][Full Text] [Related]
19. Suppressor of Cytokine Signaling 3 Is an Inducible Host Factor That Regulates Virus Egress during Ebola Virus Infection.
Okumura A; Rasmussen AL; Halfmann P; Feldmann F; Yoshimura A; Feldmann H; Kawaoka Y; Harty RN; Katze MG
J Virol; 2015 Oct; 89(20):10399-406. PubMed ID: 26246577
[TBL] [Abstract][Full Text] [Related]
20. Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease.
Brannan JM; Froude JW; Prugar LI; Bakken RR; Zak SE; Daye SP; Wilhelmsen CE; Dye JM
J Infect Dis; 2015 Oct; 212 Suppl 2():S282-94. PubMed ID: 25943199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
